ICON Public Limited (NASDAQ:ICLR - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 1,620,536 shares were traded during mid-day trading, an increase of 73% from the previous session's volume of 938,055 shares.The stock last traded at $147.10 and had previously closed at $145.00.
Analysts Set New Price Targets
A number of brokerages have commented on ICLR. Royal Bank of Canada reaffirmed an "outperform" rating and set a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. William Blair reissued an "outperform" rating on shares of ICON Public in a research note on Tuesday, January 14th. TD Cowen lowered shares of ICON Public from a "buy" rating to a "hold" rating and decreased their price objective for the company from $254.00 to $157.00 in a report on Monday, April 14th. Barclays reissued an "equal weight" rating and issued a $165.00 price target (down from $240.00) on shares of ICON Public in a research report on Thursday, April 10th. Finally, Citigroup lowered their target price on shares of ICON Public from $290.00 to $215.00 and set a "buy" rating for the company in a research note on Monday, April 7th. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $223.08.
Get Our Latest Stock Analysis on ICON Public
ICON Public Trading Up 3.1 %
The stock has a market capitalization of $12.07 billion, a price-to-earnings ratio of 15.69, a price-to-earnings-growth ratio of 1.86 and a beta of 1.24. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The business has a fifty day moving average of $169.25 and a 200-day moving average of $198.88.
ICON Public (NASDAQ:ICLR - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, beating analysts' consensus estimates of $3.41 by $0.01. The firm had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. On average, equities analysts anticipate that ICON Public Limited will post 13.38 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ICON Public
Large investors have recently made changes to their positions in the company. Cloud Capital Management LLC acquired a new position in ICON Public in the first quarter valued at approximately $101,000. Transcend Capital Advisors LLC boosted its holdings in shares of ICON Public by 7.6% during the first quarter. Transcend Capital Advisors LLC now owns 1,174 shares of the medical research company's stock worth $205,000 after acquiring an additional 83 shares during the period. Wealthquest Corp acquired a new position in shares of ICON Public during the 1st quarter worth approximately $862,000. Handelsbanken Fonder AB raised its position in shares of ICON Public by 25.3% in the 1st quarter. Handelsbanken Fonder AB now owns 25,905 shares of the medical research company's stock valued at $4,533,000 after buying an additional 5,229 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of ICON Public by 22.8% in the 1st quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company's stock valued at $99,000 after purchasing an additional 110 shares in the last quarter. Institutional investors own 95.61% of the company's stock.
ICON Public Company Profile
(
Get Free Report)
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ICON Public, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICON Public wasn't on the list.
While ICON Public currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
